Login / Signup

Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".

Kim RandJuan Manuel Ramos-GoñiBülent AkmazLaia Solé-FeuJosé Carlos Armario-Hita
Published in: Dermatology and therapy (2024)
Keyphrases
  • atopic dermatitis
  • high intensity
  • early onset
  • emergency department
  • electronic health record